More than a third of NGS users plan to purchase a new sequencing system within a year, according to the survey, conducted by GenomeWeb and investment bank William Blair.
Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.
In upgrading PacBio's shares to Outperform, the investment bank also took note of potential new revenues from its Roche deal and possibly a new platform launch next year.
The survey, conducted by GenomeWeb in conjunction with investment bank William Blair, found that users operate their NGS instruments at different capacities.
NEW YORK (GenomeWeb) – Investment bank William Blair today upgraded its rating for Sequenom's shares to Outperform on expectations of continued adoption of the molecular diagnostic firm's non-invasive prenatal testing technology and recent business developments that could increase revenues.
NEW YORK (GenomeWeb News) – Piper Jaffray today upgraded Pacific Biosciences to a Neutral rating after the next-generation sequencing company announced better than expected placements of its instruments.
NEW YORK (GenomeWeb News) — William Blair today downgraded Sequenom after the San Diego-based company firm missed Wall Street estimates on the top and bottom lines in its second quarter.
